Provided by Tiger Trade Technology Pte. Ltd.

Viking Therapeutics

31.40
-0.3300-1.04%
Post-market: 31.570.1700+0.54%19:59 EST
Volume:1.58M
Turnover:49.96M
Market Cap:3.55B
PE:-14.81
High:32.14
Open:31.75
Low:31.20
Close:31.73
52wk High:43.15
52wk Low:18.92
Shares:113.04M
Float Shares:109.98M
Volume Ratio:0.63
T/O Rate:1.44%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-2.1195
EPS(LYR):-1.0085
ROE:-29.23%
ROA:-20.48%
PB:4.98
PE(LYR):-31.14

Loading ...

Viking Therapeutics Inc. Files Initial Statement of Beneficial Ownership for Chief Commercial Officer Neil William Aubuchon

Reuters
·
Yesterday

Viking Therapeutics Showcases Advancements in Obesity and Metabolic Disease Pipeline in New Corporate Presentation

Reuters
·
Jan 15

Appetite for weight-loss deals broader than visible, Viking CEO says

Reuters
·
Jan 13

Viking Therapeutics Reports Phase 2 Trial Shows VK2735 Achieves Up to 14.7% Weight Loss in Obesity Patients

Reuters
·
Jan 12

Viking Therapeutics Announces Publication of Results From Phase 2 Venture Trial of Dual Glp-1/Gip Receptor Agonist Vk2735 in the Journal Obesity

THOMSON REUTERS
·
Jan 12

Viking Therapeutics (VKTX) Receives a Buy from Maxim Group

TIPRANKS
·
Jan 09

Viking Therapeutics: Timely VK2735 Clinical Progress and Flexible Dosing Drive Favorable Risk‑Reward and Buy Rating

TIPRANKS
·
Jan 09

Positioning Viking Therapeutics’ VK2735 as a Differentiated, Best-in-Class Obesity Franchise with Compelling Monthly Maintenance Potential Supporting a Buy Rating

TIPRANKS
·
Jan 08

Viking Therapeutics Completes Enrollment for VK2735 Obesity Maintenance Dosing Study

Reuters
·
Jan 08

Viking Therapeutics Announces Completion of Enrollment in Maintenance Dosing Clinical Trial of Vk2735 in Obesity

THOMSON REUTERS
·
Jan 08

Will Viking Therapeutics’ New CCO Reframe VKTX’s Obesity Strategy Amid Intensifying GLP-1 Competition?

Simply Wall St.
·
Jan 08

Weight-Loss Drugmakers' Stocks Jump. Structure Therapeutics up 5%; Eli Lilly Rises 4% to Record High; Amgen up 3%; Roche, Novo up Around 2%

Tiger Newspress
·
Jan 07

Press Release: Viking Therapeutics Announces Appointment of Neil Aubuchon as Chief Commercial Officer

Dow Jones
·
Jan 07

Weight-Loss Drugmakers' Stocks Jump. Arrowhead up over 17%; Structure Therapeutics up over 6%; Novo Nordisk up 5%; Viking, Pfizer, Eli Lilly up Around 2%

Tiger Newspress
·
Jan 06

12 Days of Christmas? 12 Stocks That Are Gifts for 2026

Dow Jones
·
Dec 25, 2025

FACTBOX-Weight-loss drug developers line up to tap lucrative market as competition heats up

Reuters
·
Dec 12, 2025

Weight-Loss Drugmakers' Stocks Jump. Structure Therapeutics up over 6%; Novo Nordisk, Roche up Nearly 4%; Eli Lilly up Slightly

Tiger Newspress
·
Dec 10, 2025

Top Calls on Wall Street: Nvidia, Apple, Tesla, Micron, Viking, Netflix, Hims, Delta & More

Tiger Newspress
·
Dec 09, 2025

Viking Therapeutics Showcases Advancements in Obesity and Metabolic Disease Drug Pipeline

Reuters
·
Dec 09, 2025

BUZZ-Structure Therapeutics down ahead of weight-loss drug data

Reuters
·
Dec 08, 2025